Cardiol Therapeutics (TSE:CRDL) Stock Price Down 7.9% – Should You Sell?

Cardiol Therapeutics Inc. (TSE:CRDL) shares fell 7.9% on Monday . The company traded as low as C$1.39 and last traded at C$1.39. 142,880 shares traded hands during trading, an increase of 34% from the average session volume of 106,860 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Trading Down 17.2%

The firm has a market capitalization of C$125.00 million, a PE ratio of -3.05 and a beta of 1.31. The firm’s fifty day moving average is C$1.50 and its two-hundred day moving average is C$1.65. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. On average, equities analysts predict that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.